News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Bristol-Myers Squibb Company (BMY) Drops Alzheimer's Drug on Little Benefit



12/4/2012 8:00:16 AM

Bristol-Myers Squibb Co. (BMY) ended development of an experimental Alzheimer’s disease treatment after the drug was shown not to be effective, the company said. The drug, avagacestat, was in the second of three phases of clinical development needed for U.S. regulatory approval. Bristol-Myers, based in New York, said data from a completed trial of the drug and a current study showed the therapy wasn’t effective enough to move into the final phase. “No new safety issues emerged in this interim analysis; however, the efficacy observed did not justify further development when evaluated in the context of all avagacestat data,” the company said in a statement. Alzheimer’s is a neurodegenerative disease that robs patients of their memory and ability to function. It affects 5.4 million Americans, according to the Alzheimer’s Association, and is the sixth-leading cause of death in the U.S.

Read at BusinessWeek
Read at Fox News
Read at News Release


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES